Pfizer Inc. (PFE)

36.26
NYSE : Health Technology
Prev Close 36.26
Day Low/High 0.00 / 0.00
52 Wk Low/High 31.67 / 39.43
Avg Volume 20.32M
Exchange NYSE
Shares Outstanding 5.96B
Market Cap 206.60B
EPS 3.60
P/E Ratio 13.68
Div & Yield 1.36 (3.58%)

Latest News

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Let's see what barriers may need to be passed before it heads its way higher.

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-04965842, An Oral JAK1 Inhibitor, For The Treatment Of Patients With Moderate-to-Severe Atopic Dermatitis

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-04965842, An Oral JAK1 Inhibitor, For The Treatment Of Patients With Moderate-to-Severe Atopic Dermatitis

Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Jim Cramer tackles the volatility issue and outlines the game plan for next week.

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced The Risk Of Metastasis Or Death By 71 Percent In Men With Non-Metastatic Castration-Resistant Prostate Cancer

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced The Risk Of Metastasis Or Death By 71 Percent In Men With Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Pfizer Inc.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Intermediate Trade: Pfizer

Intermediate Trade: Pfizer

I prefer a bullishly biased vertical call spread.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Video: This Strategist Wants You to Take Advantage of the Recent Market Pullback

Video: This Strategist Wants You to Take Advantage of the Recent Market Pullback

It's time to start putting money to work in the stock market, thanks to this week's stock market pullback, especially if you have been sitting on the sidelines, according to one expert.

Dow Tumbles 362 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles 362 Points; S&P 500 and Nasdaq Also Finish Lower

The Dow, S&P 500 and Nasdaq all lost ground on Tuesday.

Dow Braces for Second Triple-Digit Decline as Global Stocks Retreat

Dow Braces for Second Triple-Digit Decline as Global Stocks Retreat

The Dow is poised for its second consecutive triple-digit decline Tuesday as global investors pull back from record high stocks amid a rise in government bond yields and concerns over valuations in the tech sector.

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

You might actually be grateful that stocks took one on the jaw on Monday.

Dow Selloff, Thomson Reuters, Jamie Dimon, Exxon, Waymo - 5 Things You Must Know

Dow Selloff, Thomson Reuters, Jamie Dimon, Exxon, Waymo - 5 Things You Must Know

The Dow is looking at its second consecutive triple-digit decline on Tuesday, Thomson Reuters confirms it's in talks to sell a stake in its financial and risk business, and Jamie Dimon says he'll stay at JPMorgan Chase for five more years.

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2017 and provided 2018 financial guidance.

Jim's Daily Rundown

Jim discusses an analyst upgrade of Allergan, the super cycle concerns of Apple and how it impacts Broadcom, defense names in the bullpen, and a busy week of earnings.

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Politics, Davos, news -- none of it matters as much as earnings. Here's Jim Cramer's game plan for next week.

Jim's Daily Rundown

Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®

Pfizer Inc. (NYSE:PFE) today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera ® (rituximab-EU), met its primary endpoint.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

TheStreet Quant Rating: B (Buy)